Calidi Biotherapeuticsの空売り状況は、投資家がCalidi Biotherapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Calidi Biotherapeutics (AMEX:CLDI) 株価情報, 空売り情報

Calidi Biotherapeutics

Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

News

Pre-Market Outlook

Markets

Movers

AYRO

CLDI

CLNN

GDHG

GOOGL

MREO

OBLG

ORCL

PETS

PIXY

SRFM

THMO

TNXP

WLGS

オラクル・コーポレーション (NYSE:ORCL) の株価は、同社が第4四半期決算を発表した後、本日のプレマーケット取引で急騰しました。オラクルは自社の2021年4月～6月期決算において、予想を下回る決算を発表しました。同社は、アルファベット（Alphabet Inc）（NASDAQ:GOOGL）（NASDAQ:GOOG）のGoogle Cloudと提携することも発表しました。

オラクルの株価9%上昇の理由

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics Inc

&nbsp;
Fiscal 2025 Outlook
The Company is introducing its fiscal 2025 outlook. The Company expects:
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Fiscal
2025 Outlook
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Number of new stores</td>
<td colspan="1" rowspan="1">4 to 6</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Number of relocations/remodels</td>
<td colspan="1" rowspan="1">2 to 4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Daily average comparable store sales growth</td>
<td colspan="1" rowspan="1">4.0% to 6.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted earnings per share</td>
<td colspan="1" rowspan="1">$1.52 to $1.60</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures (in millions)</td>
<td colspan="1" rowspan="1">$36 to $44</td>
</tr>
</tbody>
</table>

Guidance

NGVC

Natural Grocers by Vitamin Cottage Sees FY25 EPS $1.52-$1.60; 4-6 New Stores; 2-4 Remodels; Daily Average Comparable Store Sales Growth 4%-6%

Earnings

UGI Corp Sees FY25 Adj. EPS $2.75-$3.05

WIIM

ESTC

Elastic shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY25 guidance above estimates.

U.S. small-cap stocks are delivering a standout performance in November, aligning with a well-established seasonal trend that often paves the way <a href="https://www.benzinga.com/news/small-cap">for a strong December.</a>
Historically, small caps tend to excel in the final two months of the year, with November&#8217;s impressive gains often rolling into December as part of the so-called &#8220;Santa Rally.&#8221;
The Russell 2000 index, the leading benchmark for small-cap equities, has climbed an impressive 8% this November, on track for the second-best monthly performance of the year.
See Also: <a href="https://www.benzinga.com/tech/24/11/42123646/google-anthropic-deal-in-jeopardy-as-us-justice-department-looks-to-snap-online-search-monopoly">Google, Anthropic Deal In Jeopardy As Regulators Look To Break Up Search Monopoly</a>
Data spanning more than two decades shows that November delivered the highest average returns for small-cap stocks.
From the year 2000 onward, the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), has averaged a 2.6% gain in November, marking it as the strongest month of the year. 
What's even more striking is the reliability of this trend—79% of the time, the month ends with small-cap stocks in the green. 
The Russell 2000 has ended November in negative territory only four times:
<ul>
<li>A decline of 9.97% in 2000, </li>
<li>6.97% in 2007, </li>
<li>11.93% in 2008, and </li>
<li>4.33% in 2021.</li>
</ul>
In all other years, small-cap stocks have delivered gains during the month. The strongest rally occurred in November 2020, when the Russell soared 18.24% buoyed by the discovery of the Covid-19 vaccine.
Yet, history suggests this isn't the time to cash out just yet. Investors tempted to take profits after November's gains might reconsider, as December historically ranks as the second-best month for small caps. 
On average, the Russell 2000 rose 1.46% in December, with 67% of years showing positive performance. The combination of these two months often gives small-cap investors a powerful year-end boost.
<h3 class="wp-block-heading">Russell 2000 Monthly Seasonality: November And December Show The Highest Average Gains</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="449" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21151452/image-233-1024x449.png" alt="" class="wp-image-659736" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21151452/image-233-1024x449.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21151452/image-233-300x131.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21151452/image-233-768x336.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21151452/image-233-1536x673.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21151452/image-233.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Why Are Small Caps Outperforming in November 2024?</h2>
As of late November, the Russell 2000's 8% rally far surpasses the 4% rise of the S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>). This outperformance is being driven by three major catalysts:
<h3 class="wp-block-heading">1. Federal Reserve Rate Cuts</h3>
The Federal Reserve has shifted into rate-cut mode, lowering rates by 25 basis points in November following a 50-basis-point reduction in September. Policymakers have signaled that further cuts are likely, albeit at a slower pace, as long as inflation continues to decelerate.
Lower interest rates disproportionately benefit small-cap companies, which rely more heavily on bank financing than their larger-cap counterparts. With borrowing costs falling, small businesses are better positioned to invest, grow, and improve profitability, giving them a significant tailwind compared to multinational firms.
<h3 class="wp-block-heading">2. Political Tailwinds From 2024 Elections</h3>
The outcome of the 2024 U.S. elections — a Republican trifecta (presidency, Senate and House of Representatives) — has fueled optimism among small-cap investors expecting the Trump administration to roll back regulations. 
Additionally, the potential reintroduction of trade tariffs could act as a buffer for small-cap businesses by reducing competition from international firms facing higher regulatory or import costs. Financial services and industrial stocks, heavily represented in small-cap indices, have been among the top beneficiaries of this shift.
<h3 class="wp-block-heading">3. Economic Resilience</h3>
The U.S. economy is showing remarkable resilience by delivering strong GDP growth rates. The Atlanta Fed's GDPNow estimate pegs fourth-quarter real GDP growth at 2.6%, following robust gains of 3.0% and 2.8% in the second and third quarters, respectively.
The labor market, a key indicator of economic health, also remains resilient. Despite disruptions from strikes and hurricanes affecting October payrolls data, jobless claims have fallen to their lowest levels in seven months in mid-November, indicating a tight labor market and sustained consumer confidence. These factors collectively underpin the performance of small-cap stocks, which are often more sensitive to domestic economic trends.
<h3 class="wp-block-heading">What's Next For Small Caps?</h3>
With November's gains already in the books, historical patterns suggest that small caps could keep their momentum into December. Whether fueled by seasonal trends, macroeconomic tailwinds, or political optimism, small-cap stocks are positioning themselves as a standout opportunity for year-end trading.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42118286/7-us-natural-gas-stocks-to-watch-as-henry-hub-prices-surge-50-in-november">7 US Natural Gas Stocks To Watch As Henry Hub Prices Surge 50% In November</a></li>
</ul>
Image: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Small Cap

Econ #s

Economics

ETFs

November Small-Cap Surge Could Carry Into December's Santa Rally, Historical Trends Suggest

Grabowski continues to beneficially own 24% of the Company's Common Stock.

XPOF

Xponential Fitness Says On November 21, Entities Affiliated With Chairman Mark Grabowski Filed Form 144 Disclosing Sale Of 2.59M Shares Of Company's Class A Common Stock - Filing

BTDR

Bitdeer Technologies shares are trading lower after the company announced a proposed $360 million private placement of convertible senior notes due 2029.

UGI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UGI#NYSE">UGI</a>) reported quarterly earnings of $3.06 per share which beat the analyst consensus estimate of $2.94 by 4.08 percent. The company reported quarterly sales of $7.21 billion which missed the analyst consensus estimate of $8.45 billion by 14.64 percent.

Earnings Beats

Earnings Misses

UGI FY 2024 Adj EPS $3.06 Beats $2.94 Estimate, Sales $7.21B Miss $8.45B Estimate

Natural Grocers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVC#NYSE">NGVC</a>) reported quarterly earnings of $0.39 per share. This is a 50 percent increase over earnings of $0.26 per share from the same period last year. The company reported $322.66 million in sales this quarter. This is a 9.35 percent increase over sales of $295.07 million the same period last year.

Natural Grocers Q4 EPS $0.39 Up From $0.26 YoY, Sales $322.66M Up From $295.07M YoY

LGTY

Logility Supply Chain Solutions shares are trading lower after the company reported worse-than-expected Q2 revenue results and issued FY25 revenue guidance below estimates.

REPL

Replimune Group shares are trading higher after the company announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.

Management

GOGO

Gogo Says Sergio Aguirre Announced His Retirement As President And COO, Effective December 31, 2024 - Filing

Dividends

BF/A

BF/B

Brown-Forman Corporation Increase Quarterly Dividend From $0.2178 To $0.2265

VRPX

Virpax Pharmaceuticals shares are trading higher after the company announced an agreement with the US HHS department for an extension towards its cooperative research and development.

MDB Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDBH#NASDAQ">MDBH</a>) reported quarterly losses of $(0.83) per share. This is a 69.39 percent decrease over losses of $(0.49) per share from the same period last year.

MDBH

MDB Capital Holdings Q3 EPS $(0.83) Down From $(0.49) YoY

Alta Global Group shares are trading higher. The company announced it filed a request to withdraw its Form F-1 registration with the SEC.

Retail Sales

SONM

Sonim Technologies Announced It Just Unveiled The New XP Pro 5G Next Generation Ultra Rugged Smartphone Supporting Verizon's 5G Ultra Wideband

MATW

Matthews International shares are trading higher after the company reported better-than-expected Q4 EPS and sales.

MODD

Modular Medical shares are trading lower after the company announced a proposed public offering.

CETX

Cemtrex shares are trading lower after the company announced its board approved a 1-for-35 reverse stock split.

Buybacks

CBRE

CBRE Announces Expanded Stock Repurchase Authorization Of Up To $5B

Warning: CLDI is at high risk of performing badly

Calidi Biotherapeutics GAAP EPS of -$0.65

Calidi Biotherapeutics announces proposed offering

Calidi (CLDI) Biotherapeutics announced that it intends to offer to sell shares of its common stock in an public offering. All of the shares of com...

Calidi announces common stock offering, no amount given

Calidi Biotherapeutics announces pricing of $7.5M public offering of common stock

Calidi (CLDI) Biotherapeutics has priced its public offering of 4,437,869 shares of the Company's common stock at a price of $1.69 per share. The c...

Calidi prices 4.4M shares at $1.69 in public offering

Calidi Biotherapeutics ( ($CLDI) ) has provided an update. Calidi Biotherapeutics has unveiled promising data showcasing its innovative RTNova syst...

Calidi Biotherapeutics Reveals Promising Virotherapy Data

Calidi (CLDI) Biotherapeutics presented data at the International Oncolytic Virotherapy Conference and the Society for Immunotherapy of Cancer Annu...

Calidi presents data on RTNova systemic technology in metastatic lung cancer

Screenshot 2024-03-05 at 6.31.45 PM

Biotech

General

CADL

CGON

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Press Releases

Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

Financing

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Announces Proposed Public Offering

IPOs

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Comments

Calidi Biotherapeutics

空売り

Calidi Biotherapeutics (AMEX:CLDI) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル